Scientific Materials

DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients

Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

Brennan S. Dirk, Genevieve Weir, Tara Quinton, Olga Hrytsenko, Marianne M. Stanford

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SPiReL Study

Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy

Marie-Laurence Tremblay, Zoe O’Brien-Moran, James A. Rioux, Andrea Nuschke, Christa Davis, W. Martin Kast, Genevieve Weir, Marianne Stanford & Kimberly D. Brewer

Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy, Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

T cell infiltration into tumors induced by DPX-Survivac combination immunotherapy demonstrated by PET/MR imaging in an orthotopic ovarian cancer model

DPX platform for Drug Delivery: Evaluation of lymph node-targeted delivery of immunomodulatory agents in DPX